Atea Pharma Rejects Unsolicited Proposal From Tang Capital Partners
Biopharmaceutical company Atea Pharmaceuticals, Inc. (AVIR) announced Tuesday that its Board of Directors unanimously rejected the unsolicited proposal from Tang Capital Partners, LP on behalf of Concentra Biosciences, LLC to acquire all outstanding common shares of Atea for $5.
Concentra Biosciences Atea Pharmaceuticals Inc Atea Pharmaceuticals Tang Capital Partners Atea Board Tea Pharmaceuticals
Source: rttnews.com